Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.73 |
| ▸ | BRD2 | P25440 | 2/20 | 0.63 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.63 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CCL2 | P13500 | 1/20 | 0.63 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.63 |
| ▸ | TACR1 | P25103 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.63 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.63 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.63 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.63 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18908663 | 1.00 | BRD4 (0.73) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL29516834 | 1.00 | BRD4 (0.73) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL29716092 | 1.00 | BRD4 (0.73) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL22054912 | 0.97 | BRD4 (0.70) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL22054921 | 0.97 | BRD4 (0.70) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL29716160 | 0.96 | BRD4 (0.69) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL29516723 | 0.96 | BRD4 (0.69) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL18908662 | 0.96 | BRD4 (0.69) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL18908717 | 0.96 | BRD4 (0.69) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL18908755 | 0.95 | BRD4 (0.69) | BRD4BRD2BRD3CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119416-A9 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-21 | — | — | US | disclosed |
| US-20210221826-A1 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-22 | — | — | US | disclosed |
| US-10913752-B2 | Bivalent bromodomain inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200172553-A9 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-04 | — | — | US | disclosed |
| WO-2017091673-A2 | BIVALENT BROMODOMAIN INHIBTORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221826-A1 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BET1, BRD2 | BRD4 1/4885BRD2 3/4885BRD3 4/4885 |
| US-10913752-B2 | Bivalent bromodomain inhibitors and uses thereof | BRD4, BRD2, BET1 | BRD4 1/4885BRD2 2/4885BRD3 4/4885 |
| US-20200172553-A9 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BET1, BRD2 | BRD4 1/4885BRD2 3/4885BRD3 4/4885 |
| US-20220119416-A9 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BET1, BRD2 | BRD4 1/4885BRD2 3/4885BRD3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.